Al Hammadi Holding Company Stocks

SAR 26.28Last Updated 27.04.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

SAR 1.10B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SAR 26.28
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Al Hammadi Company For Development and Investment establishes, maintains, manages, and operates hospitals and medical centers in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments. It is also involved in the wholesale and retail trading of medical equipment, pharmaceutical and cosmetic products, and food and beverages; and the acquisition and rental of land for constructing buildings. In addition, the company invests in various industrial projects; and establishes, operates, and maintains commercial centers. It operates three hospitals under the Al Hammadi Hospital name in Olaya, Suwaidi, and Al Nuzha districts of Riyadh. The company was founded in 1985 and is based in Riyadh, the Kingdom of Saudi Arabia.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 4007.SR is 43 and suggests 64% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks